Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals

Sponsor
Acibadem University
Study ID
NCT07609160
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Obesity
  • Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
  • Sarcopenia

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Resistance exercise — OTHER
    A 24-week home-based resistance exercises using elastic band and bodyweight
  • Lifestyle recommendations — OTHER
    Lifestyle recommendations including physical activity and nutritional advice

Study Details

This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.

Key Dates

First listed
May 27, 2026
Start date
Nov 1, 2026
Status verified
Apr 2026
Primary completion
Nov 30, 2027
Completion
Jan 1, 2028

Study Design

Enrollment
108 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Resistance Exercise + Tirzepatide
    24-week home-based progressive resistance exercise program (3 sessions/week) using elastic bands and bodyweight exercises, combined with tirzepatide treatment and general lifestyle recommendations..
  • Active Comparator: Tirzepatide Alone
    Standard tirzepatide treatment with usual care and general lifestyle recommendations.

Primary Outcome Measure

Change in muscle thickness [ Time Frame: Baseline, 12 weeks, 24 weeks ]

Central Contacts

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies